| Drug Name | GPCR-targeted Project 005 |
| Description |
Prokineticins (PK1 and PK2) are peptide hormones that exert their biological activities, such as modulating cell survival, cell motility, and cell excitability, through two common G-protein-coupled receptors: prokineticin receptor (PKR) 1 and 2. A monoclonal antibody is being developing as an inhibitor of prokineticin receptor 1 (PKR1) for the treatment of inflammation. Early research is under way. |
| Target | Prokineticin receptor 1 (PKR1) |
| Drug Modality | Monoclonal antibody |
| Indication | Inflammation |
| Product Category | Biologic |
| Mechanism of Action | PKR1 inhibitors |
| Status | Preclinical |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |